Harbour BioMed, Sinopharm Form Innovation R&D Consortium
Cambridge, MA, Rotterdam, Netherlands, and Shanghai, China – July 27, 2026 Harbour BioMed has entered into a strategic collaboration...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Cambridge, MA, Rotterdam, Netherlands, and Shanghai, China – July 27, 2026 Harbour BioMed has entered into a strategic collaboration...
CAMBRIDGE, Massachusetts, July 23, 2026 Nona Biosciences has announced a strategic research collaboration with the Medical University of Vienna...
CAMBRIDGE, Massachusetts, July 1, 2026 Nona Biosciences has entered into a strategic collaboration with Lonza to develop a next-generation...
NEW YORK, June 15, 2026 Enhanced Group Inc. has announced a $50 million strategic equity financing through a private...
CAMBRIDGE, Mass., ROTTERDAM, Netherlands, and SHANGHAI, China, June 15, 2026 Harbour BioMed and BioMap have announced a long-term strategic...
CAMBRIDGE, Massachusetts, ROTTERDAM, Netherlands, and SHANGHAI, China, June 14, 2026 Harbour BioMed has secured a major legal victory in...
